Infliximab Partially Alleviates the Bite Force Reduction in a Mouse Model of Temporomandibular Joint Pain.
10.3346/jkms.2015.30.5.552
- Author:
Sang Hyon KIM
1
;
Chang Nam SON
;
Hyo Jung LEE
;
Ho Chan CHO
;
Sung Won JUNG
;
Ji An HUR
;
Won Ki BAEK
;
Hye Ra JUNG
;
Ji Hee HONG
Author Information
1. Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Bite Force;
Infliximab;
Temporomandibular Joint Pain
- MeSH:
Animals;
Antirheumatic Agents/*therapeutic use;
*Bite Force;
Disease Models, Animal;
Freund's Adjuvant/toxicity;
Infliximab/*therapeutic use;
Male;
Mice;
Mice, Inbred ICR;
Temporomandibular Joint/pathology;
Temporomandibular Joint Disorders/chemically induced/*drug therapy/pathology;
Time Factors
- From:Journal of Korean Medical Science
2015;30(5):552-558
- CountryRepublic of Korea
- Language:English
-
Abstract:
Temporomandibular joint (TMJ) disorder is clinically important because of its prevalence, chronicity, and therapy-refractoriness of the pain. In this study, we investigated the effect of infliximab in a mouse model of TMJ pain using a specially-engineered transducer for evaluating the changes in bite force (BF). The mice were randomly divided into three groups (7 mice per group): the control group, the complete Freund's adjuvant (CFA) group, and the infliximab group. BF was measured at day 0 (baseline BF). After measuring the baseline BF, CFA or incomplete Freund's adjuvant was injected into both TMJs and then the changes in BF were measured at days 1, 3, 5, 7, 9, and 13 after the TMJ injection. For measuring the BF, we used a custom-built BF transducer. Control, CFA, and infliximab groups showed similar baseline BF at day 0. From day 1, a significant reduction in BF was observed in the CFA group, and this reduction in BF was statistically significant compared to that in the control group (P < 0.05). This reduction in BF was maintained until day 7, and BF started to recover gradually from day 9. In the infliximab group also, the reduction in BF was observed on day 1, and this reduction was maintained until day 7. However, the degree of reduction in BF was less remarkable compared to that in the CFA group. The reduction in BF caused by injection of CFA into the TMJ could be partially alleviated by the injection of anti-tumor necrosis factor alpha, infliximab.
